Close Menu

Tacere Therapeutics

Benitec Biopharma hit two key milestones recently in its effort to advance its expressed RNAi-based hepatitis C treatment TT-034 into the clinic, securing a commitment to sell A$7 million ($6.7 million) of its stock to new and existing shareholders and receiving a favorable revie

Shares of Benitec Biopharma resumed trading on the Australian Stock Exchange this week after the company announced that it had closed a A$800,000 ($821,760) private placement that it said would give it resources enough to fund a clinical trial of its recently reacquired hepatitis

Two years after the US Patent and Trademark Office reinstated its core patent, Australia's Benitec Biopharma has once again set its sights on finding licensees for its expressed RNAi intellectual property.

Benitec Biopharma last week said that it has completed its acquisition of Tacere Therapeutics, which was first announced last month.

With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.

Just six years after a troubled Benitec Biopharma licensed its expressed RNAi hepatitis C drug program to Tacere Therapeutics, a startup founded by former Benitec executives, the two companies have agreed to merge.

Rosetta Genomics announced that it has named Robert Wassman as its new chief medical officer and Dganit Bar as its new chief scientific officer.

Tacere Therapeutics is prepared to file an investigational new drug application for an expressed RNAi treatment for hepatitis C, but is looking to partner the program before doing so after previous collaborator Pfizer pulled back on its in-house RNAi drug efforts, according to Be

Although Pfizer's license to the HCV program in markets outside of Asia remains in effect, major restructuring at the big pharma has raised questions about the future of the arrangement.

Benitec gained an equity stake in Tacere as part of a 2006 technology-licensing deal between the firms.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.